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While most experts agree that cervical screening is effective, there remains controversy over the most appropriate screening interval.
Annual screening is common in North America. In England, some argue for 3-yearly screening while others believe 5-yearly screening
is adequate, and the frequency varies from one part of the country to another. Screening histories of 1305 women aged 20–69 years,
diagnosed with frankly invasive cervical cancer and 2532 age-matched controls were obtained from UK screening programme
databases. Data were analysed in terms of time since last negative, and time since last screening smear. Five-yearly screening offers
considerable protection (83%) against cancer at ages 55–69 years and even annual screening offers only modest additional
protection (87%). Three-yearly screening offers additional protection (84%) over 5-yearly screening (73%) for cancers at ages 40–54
years, but is almost as good as annual screening (88%). In women aged 20–39 years, even annual screening is not as effective (76%)
as 3-yearly screening in older women, and 3 years after screening cancer rates return to those in unscreened women. This calls into
question the policy of having a uniform screening interval from age 20 to 64 years and stresses the value of screening in middle-aged
women.
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While most experts agree that cervical screening is effective, there
remains controversy over the most appropriate screening interval.
Annual screening is common in North America (even in women
who have been screened several times previously), while 5-yearly
screening is provided by some European countries. Here, we
estimate the benefits of screening at different intervals and at
different ages from a large population-based case–control study.
Following the relaunch of the National Cervical Screening
Programmes in the United Kingdom in 1988, we initiated a
protocol to monitor its effectiveness. Originally under the auspices
of the National Coordinating Network and more recently with the
support of the National Screening Office, we have been collecting
data on the screening histories of all women from self-selected
Health Authorities and Health Boards (HAs) with newly diagnosed
cancer and a small control of sample women without cervical
cancer. We previously reported results on 5 years of screening in
1025 women, including 348 with cancer (Sasieni et al, 1996). The
full data set now has over 2500 women with cancer. Here we
analyse data on 1305 women diagnosed with stage 1B or worse
cervical cancer between the ages of 20 and 69 years, and 2532
controls with a total of approximately 40000 women-years of
screening (35000 since 1988). Approximately 90% of cases in this
report were not included in the previous report. The rationale for
restricting attention to frankly invasive cancer is that ideally these
should all be prevented by screening, whereas microinvasive
cancers are mostly screen-detected and have an extremely good
cure rate.
MATERIALS AND METHODS
The methods have been described previously (Sasieni et al, 1996).
The participating HAs have changed over the years due to
boundary changes and changes in personnel. Areas that con-
tributed data and the years for which they contributed are listed in
the Acknowledgements. Data were collected by local coordinators
as part of audit. Cases were identified from pathology laboratories
and confirmed to have been resident in the HA at diagnosis. Data
recorded included the date of diagnosis and, where possible, the
stage and histology of the cancers. Age-matched controls, for each
case, were identified from among women (not known to have had a
hysterectomy) registered with a group practice (GP) in the same
area. One control was selected from the same GP, the other from
another GP in the same area. Screening histories (including the
dates and results of all smears) were downloaded from the Exeter
computer system and checked against information held by
cytology laboratories. The Exeter system is used to run the
screening programme and stores screening histories of all women
registered with a GP. All smears in this study were prepared by
conventional (as opposed to liquid-based) cytology and classified
according to a version of the British Society for Clinical Cytology
(BSCC) system (Johnson and Patnick, 2000).
In all analyses, a case’s date of diagnosis was used as a pseudo-
date of diagnosis for her matched controls, and only smears taken
prior to that date were considered. All smears in teenagers were
Received 6 February 2003; revised 21 March 2003; accepted 21 March
2003
*Correspondence: Dr P Sasieni; E-mail: peter.sasieni@cancer.org.uk
British Journal of Cancer (2003) 89, 88–93













yexcluded because they are not part of the screening programme
and are likely to identify a high-risk group. Odds ratios and their
confidence intervals (CIs) were estimated by conditional logistic
regression (Breslow and Day, 1980). As cervical cancer is a rare
disease, odds ratios are interpreted as relative risks (RRs) and are
referred to as such. Age groups refer to the age at diagnosis, not
the age at which the smear was taken.
One measure of exposure is the time between the last
‘operationally’ negative smear and (pseudo-) diagnosis. An
operationally negative smear is defined as a negative smear not
preceded by an abnormal smear (borderline or worse) within the
previous 12 months. A second measure of exposure is the time
prior to diagnosis of the most recent adequate screening smear
(regardless of result) ignoring all smears within 6 months of
diagnosis. A screening smear is defined here to be one that was not
preceded (at any time) by an abnormal smear. An adequate smear
is one that was not classed as inadequate (for making a good
cytological classification).
To estimate the protection from frankly invasive cervical cancer
by being screened once every 3 years, we calculate the mean of the
RRs for 0.5–1.5, 1.5–2.5 and 2.5–3.5 years, and similarly for 5
years. For ‘time since last negative’, the first interval is 0–1.5 years
and is weighted accordingly when calculating the mean. The
proportion preventable is one minus the mean RR.
RESULTS
The database includes 2753 women with invasive cervical cancer
diagnosed between 1990 and 2001 (91% between 1992 and 1998).
Their age distribution (Table 1) is extremely similar to that of all
cases registered in the UK for 1993–1997. Those aged over 69 (521)
or under 20 (one) and those others with microinvasive cancer
(526) or unknown stage (400) were excluded. Table 2 provides an
age breakdown of the remaining 1305 cases and their 2532
controls, and gives the proportion screened in each group. All
subsequent analyses relate to the cases (aged 20–69 years with
frankly invasive cervical cancer) and controls described in Table 2.
The risk of developing cervical cancer is less in the years
following an operationally negative smear and the magnitude of
this effect decreases (the RR increases) with increasing time since
the last negative smear (Table 3 and Figure 1). The results differ
between age groups. Relative to those who have never had a
negative smear, women aged 40–69 years (at the end of the
interval) are very unlikely (RR 0.12 and 0.13 for those aged 40–54
and 54–69 years, respectively) to develop cervical cancer within 3
years of a negative smear. Those aged 55–69 years are still
moderately unlikely (RR¼0.20) to develop cancer 3–5 years after
a negative smear, and remain at lower risk (RR¼0.45) for well
over 5 years. For women aged 40–54 years, the risk increases more
rapidly: RR¼0.39 after 3–5 years, with close to the background
risk after 5 years. In younger women, protection is weaker and
even more time restricted: RR¼0.24 in the first year, RR¼0.28
over the first 3 years, and there is no effect 3–5 years after a
negative smear (RR¼1.03). In those aged 20–39 years at
diagnosis, the risk more than 5 years after a negative smear is
significantly greater than in those who have never had a negative
smear.
In young women, having a last negative smear over 5 years ago
is associated with a doubling of risk compared to women who
never had a negative smear. The estimates could be confounded by
demographics: women who go for regular screening may have a
different underlying risk of disease than those who are only
screened infrequently or those who never attend screening.
Excluding the district controls and comparing cases only to their
GP controls had little overall effect on the results. Similarly,
excluding all smears taken before 1988 because of concern of
‘information bias’ in the preferential recording of historic smears
in cases had minimal effect (results not shown).
Figure 1 illustrates the RR of cancer as a function of time since
the last negative smear calculated using 6-monthly intervals. Note
the substantial jumps (approximately two-fold) either side of 3 and
5 years. Further, in each age group, the estimated RR 3–3.5 years
after a negative smear is greater than after 3.5–4 years.
Relative risks as a function of time since the last adequate smear
(excluding smears within 6 months of diagnosis) are shown in
Table 4. Notice that (i) the RRs are generally greater than in Table
3, (ii) the risk in the period 0–1.5 years is always greater than that
for 1.5–2.5 years, and (iii) there is only a modest effect of
screening in those aged 20–39 years at diagnosis.
Table 5 provides a summary of the estimated proportion of
cancer that could be ‘prevented’ by screening every one, 3 or 5
years. The estimates obtained using the two different methods of
analysis are similar, although, as expected, the estimates based on
the time since the last negative smear are generally greater. The
consistent finding is that the proportion of cancer preventable by
screening increases with age, but both the absolute and the relative
advantage of 3- vs 5-yearly screening decreases with age.




Age group (years) 1A 1B+ Unknown Total UK 1993–1997 (%)
o20 0 (0.0%) 1 (0.1%) 0 (0.0%) 1 (0.0%) 0.1
20–24 18 (3.3%) 13 (0.8%) 3 (0.6%) 34 (1.3%) 1.3
25–39 291 (54.2%) 425 (24.6%) 157 (32.1%) 873 (31.7%) 28.7
40–54 156 (29.1%) 481 (27.9%) 147 (30.0%) 784 (28.5%) 26.9
55–69 61 (11.4%) 386 (22.4%) 93 (18.9%) 540 (19.6%) 19.8
70+ 11 (2.0%) 420 (24.3%) 90 (18.4%) 521 (18.9%) 23.2
Total 537 (100%) 1726 (100%) 490 (100%) 2753 (100%) 100
Values in italics indicate the data analysed in the paper.
Table 2 Percentage of women with at least one recorded smear more
than 6 months prior to (pseudo-) diagnosis by age group and disease status
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These analyses provide quantitative estimates of the benefit of
different screening intervals at different ages. We have considered
cancers regardless of histological type because it is not possible to
set one screening interval for the prevention of squamous
cell carcinoma and another for adenocarcinoma. Although
cytological screening may be less effective against adeno-
carcinoma, it appears to have a substantial impact (Sasieni and
Adams, 2001).
Table 3 Odds ratios (with 95% confidence intervals) for frankly invasive cervical cancer by time since the last
operationally negative cytological smear
Age group (years)
20–39 (n¼438) 40–54 (n¼481) 55–69 (n¼386)




Model A (years since last negative smear)
0–1.5 0.24 (0.16–0.37) 0.12 (0.08–0.18) 0.13 (0.08–0.22)
1.5–2.5 0.33 (0.21–0.51) 0.14 (0.08–0.22) 0.13 (0.07–0.23)
2.5–3.5 0.67 (0.43–1.04) 0.25 (0.16–0.40) 0.15 (0.08–0.26)
3.5–4.5 1.06 (0.65–1.72) 0.30 (0.18–0.50) 0.18 (0.09–0.34)
4.5–5.5 1.40 (0.75–2.62) 0.61 (0.34–1.09) 0.28 (0.14–0.57)
5.5–6.5 1.86 (0.88–3.93) 0.72 (0.36–1.43) 0.33 (0.14–0.79)
Over 6.5 2.37 (1.16–4.85) 0.69 (0.36–1.34) 0.55 (0.27–1.10)
One negative only 1.00 (0.70–1.41) 1.31 (0.90–1.91) 1.39 (0.88–2.21)
Model B (years since last negative smear)
0–2.9 0.28 (0.20–0.41) 0.12 (0.08–0.17) 0.13 (0.08–0.19)
3.0–4.9 1.03 (0.68–1.56) 0.39 (0.26–0.58) 0.20 (0.12–0.33)
Over 5.0 2.05 (1.20–3.49) 0.72 (0.43–1.18) 0.45 (0.25–0.81)
One negative only 1.03 (0.73–1.46) 1.32 (0.91–1.91) 1.35 (0.85–2.14)
aBaseline. (A) Analysis by single year since last negative. (B) Analysis using grouped time since last negative. Both models include a
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Figure 1 Relative risk of cervical cancer as a function of time since last operationally negative smear. The risks are calculated in 6-monthly intervals. The
horizontal dotted lines mark the 95% confidence bands on the relative risks for 0–3, 3–5 and 5þ years. All estimates are relative to the risk in women who
have never had a negative smear.
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yIt is inappropriate to compare the time since the most recent
negative smear in screen-detected cases with that in randomly
selected controls (IARC, 1986; Sasieni, 2001), because for a screen-
detected case the time since her last negative smear will be her
normal screening interval plus a short period to allow for
diagnosis. It is not possible to identify which cases are screen-
detected using routine data, because approximately 50% of women
screened in England in the mid-1990s did not attend in response to
an invitation (Department of Health, 1996). Even if GP notes were
examined, it is doubtful whether one could distinguish between
symptoms reported during a routine screening examination and
symptoms that lead to the consultation. By considering only
frankly invasive (stage 1Bþ) cancers, we hoped to eliminate
screen-detected cancers, but in a series of 327 such cancers from
southern England, 78 (24%) were classified as screen-detected
(Herbert et al, 2001).
Screening intervals in this study were primarily either just over 3
or just over 5 years. Hence, if screen-detected cancers are included,
the RR for 0–3 years will be artificially low, but it will increase
substantially for 3–3.5 years. This is precisely the pattern observed
(Figure 1). It is beyond the scope of this study to quantify the
extent to which women with screen-detected stage 1 cancers
benefited from screening.
Although we have used these RRs to estimate the absolute
reduction in stage 1Bþ cervical cancer that might result from 1-,
3- and 5-yearly screening, these should not be used in formal
calculations of the cost per cancer prevented since negative smears
do not prevent cancer. This method will overestimate the
proportion of cancers prevented since not all women with
abnormal smears will be prevented from developing cancer
(Sasieni et al, 1996). Nevertheless, it does provide valuable
information on the natural history of cervical precancer and of
the relative benefit of different screening intervals.
Relating incidence to the time since the most recent screen
estimates the extent to which a woman who has been screened
recently is prevented from developing cancer. However, it is
difficult to determine whether a smear was taken for screening
purposes: a high proportion of cases had at least one smear in the
months preceding diagnosis and many of these women had no
other smears on record. For that reason, we excluded all smears
taken during the 6 months immediately preceding (pseudo-)
diagnosis. A period of 6 months was chosen by examining the
proportions whose most recent smear was within various intervals
from diagnosis (Table 6). Half of all cases had a smear within 3
months of diagnosis compared to just 5% 6–12 months prior to
diagnosis. In fact, the 6-month exclusion (used in Table 4) is not
long enough to take account of all ‘diagnostic smears’ – the relative
proportions last screened 6–12 months, compared to 1–6 years,
prediagnosis is greater in cases than controls (P¼0.002).
Table 4 Odds ratios for fully invasive cervical cancer by time since last adequate cytological smear ignoring all smears
within 6 months of diagnosis
Odds ratio (95% CI)
20–39 (n¼438) 40–54 (n¼481) 55–69 (n¼386)




Time since last adequate smear
b (years)
0.5–1.5 0.77 (0.53–1.11) 0.38 (0.26–0.54) 0.42 (0.27–0.65)
1.5–2.5 0.35 (0.23–0.54) 0.22 (0.14–0.34) 0.21 (0.12–0.36)
2.5–3.5 0.65 (0.43–0.98) 0.34 (0.23–0.50) 0.18 (0.11–0.30)
3.5–4.5 0.76 (0.47–1.23) 0.28 (0.17–0.47) 0.22 (0.12–0.38)
4.5–5.5 0.98 (0.52–1.82) 0.61 (0.37–1.01) 0.32 (0.18–0.57)
5.5–6.5 1.61 (0.77–3.38) 0.80 (0.40–1.60) 0.28 (0.13–0.60)
Over 6.5 2.05 (0.89–4.68) 1.01 (0.58–1.77) 0.48 (0.26–0.89)
Exactly one screening smear 1.06 (0.79–1.44) 1.36 (1.01–1.82) 2.42 (1.77–3.33)
aBaseline.
bThese odds ratios are appropriate for women who have had two or more adequate smears. For women with just one
screening smear, they should be multiplied by the odds ratio for ‘exactly one screening smear’. Thus, for instance, a woman aged 45
years who was last screened 4 years ago and had just one smear on record would have an odds ratio of 0.38¼0.28 1.36. Multivariate
conditional logistic regression including time since last adequate smear and an indicator for those with just one screening smear. n is the
number of cases included in the analysis; there are approximately twice as many controls.
Table 5 Summary percentage preventable by 3- and 5-yearly screening (these are based on the average RRs from 0–1.5, 0 to 3.5 years and 0 to 5.5 years
from Tables 3 and 4)
20–39 years 40–54 years 55–69 years
Method Annual 3 yearly 5 yearly Annual 3 yearly 5 yearly Annual 3 yearly 5 yearly
Last negative 76% 61% 30% (39%) 88% 84% 73% 87% 87% 83%
Last adequate 41% 30% 69% 63% 73% 73%
*The percentage in parentheses is obtained by replacing RRs greater than one with 1.0 when averaging.
Table 6 Proportion of women aged 20–69 years whose most recent
smear was within different intervals
Most recent smear Control (%) 1B+ (%)
p1 month 1.6 22.5
1–3 months 4.0 27.0
3–6 months 6.0 10.1
(p6 months) (11.6) (59.6)
6 months–1 year 11.3 5.1
1–6 years 54.7 15.5
46 years 4.1 3.6
Never 18.4 16.3
Total 2532 1305
Time measure from date of (pseudo-) diagnosis.
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yAnother difficulty with identifying the last screening test is that
once a woman has been treated for a cervical lesion, she could be
put on indefinite annual follow-up. Our solution of censoring
screening histories at the first abnormal smear is not ideal and it
potentially introduces a small bias in favour of screening. Further,
the fact that the RRs (in Table 4) are greater in the first time period
than the second suggests that the 6-month exclusion is not quite
sufficient and that these RRs should not be overinterpreted.
Despite these caveats, we believe that this approach does provide
reasonable estimates of the efficacy of 3- and 5-yearly (but not
annual) screening (Table 5).
In younger women, the risk of disease in those whose last smear
was more than 5.5 years ago was greater than in those who had no
smears (Tables 3 and 4). This suggests that those who opt out of
screening altogether are at a lower underlying risk of cervical
cancer than those who are screened occasionally. Opportunistic
screening of women seeking contraceptive advice and those
attending STD clinics could account for such a trend. What then
is the appropriate baseline for estimating the RRs? We have used
those with no smears, but use of those with no recent smear would
have made the estimated effect of screening considerably greater in
young women. The RR in women aged 20–39 years, whose most
recent operationally negative smear was 3.5–4.5 years ago, was
1.06 relative to those with no such smear (Table 3). However,
relative to those whose most recent negative smear was more than
6.5 years ago, it is 0.45 (¼1.06/2.37). In our opinion, such adjusted
RRs are inappropriate: (ignoring the effect of screening) it is more
likely that those who were last screened many years ago form a
high-risk subgroup than that those who are never screened are at
low risk. But this needs to be tested by a larger, more detailed
study in young women in which risk factors for the acquisition and
persistence of HPV infection are collected along with screening
histories.
POLICY CONSIDERATIONS
Policy should be determined by balancing costs against benefits.
Although there are fixed overheads, the main cost is proportional
to the number of screening tests. Thus, 3-yearly screening will cost
60–66% more than 5-yearly screening. This is partly offset by not
having to pay for the treatment of cancers prevented, but the
financial saving is modest. The main benefits are in terms of
cancers prevented and lives saved and the latter can be converted
into years of life saved. There are also ‘negative benefits’ such as
unnecessary treatment and anxiety caused by abnormal smears.
Icelandic data show that the amount of low-grade disease (and
hence, presumably, the number of women made anxious) is
inversely proportional to the screening interval (Sigurdsson and
Adalsteinsson, 2001). One can try to combine these factors in an
overall measure of quality of life, but it is difficult to balance the
low level of anxiety provoked in many women against the
prevention of cancer in a few. It is also unclear whether giving
one woman an extra 30 years of life is equivalent to giving an extra
week to 1500 women.
Our results clearly show that cytological screening is less
effective at preventing frankly invasive cervical cancer in women
under the age of 40 than it is in women aged over 40 years. They
also suggest that cervical cancer develops more rapidly in young
women so that the incidence rate of cervical cancer 3 years after a
negative smears is the same as that in unscreened women. It is
possible that although screening is not very effective at preventing
cancer in young women, it saves lives through early diagnosis.
Indeed, in this series of 747 staged cancers in women aged 20–39
years, 41% were microinvasive.
Our results in young women differ from those reported by IARC
(1986). That paper summarised the results from three cohort
studies with a total of 148 cases aged under 35 years and found that
the protection, relative to historical incidence rates, was similar to
that seen in older women. Cases in that study were restricted to
those with squamous cancer, but included stage 1A tumours
(including any that were screen-detected). It is thus possible that
differences in the design of the studies could explain the different
results.
The RR associated with various screening intervals estimated
here will help formulate policy, but there will be other considera-
tions such as the underlying age-specific incidence rates, the
numbers of years of cancer-free life gained and the age-specific
rates of cytological abnormalities. Our own recommendations are
given in Table 7. Under the age of 25 years, invasive cancer is
extremely rare, but cytological abnormalities are common
(Department of Health, 2001). Although lesions treated in very
young women may prevent cancers from developing many years
later, the results of this paper would suggest that it is enough to
begin screening around age 25 – lesions that are destined to
progress will still be screen-detectable and those that would regress
will no longer be a source of anxiety. Nationally, only 1.7% of
cervical cancer in women aged 20–69 occur under the age of 25,
corresponding to an incidence rate of 2.5 per 100000 women-
years. In our study, 26 out of the 34 women with cervical cancer
aged 20–24 years had a previous (operationally) negative smear,
suggesting that cytology is not very sensitive for these tumours.
A review of the screening histories of the 13 women with
stage 1Bþ cervical cancer aged 20–24 indicates that six of these
cases were symptomatic, of which five were stage 1B and the other
was stage 3.
In the UK, cervical cancer rates between the ages of 25 and 40
years are only slightly lower than in older women, so effective
screening in this group is essential. However, most cancers still
occur in older women, so resources also have to be allocated to
ensure that a high proportion of women continue to be screened
(albeit less frequently) at older ages.
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